Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01869725 · ClinicalTrials.gov registry record · Phase 2
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
A Phase 2 study of Neuroblastoma and Neuroendocrine Tumor, sponsored by Sue O'Dorisio.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT01869725: Completed Phase 2 study of Neuroblastoma and Neuroendocrine Tumor, sponsored by Sue O'Dorisio.
NCT01869725 is a Phase 2 study of Neuroblastoma and Neuroendocrine Tumor that has completed, run by Sue O'Dorisio. The registered enrollment target is 68 participants, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01869725, a Phase 2 study of Neuroblastoma and Neuroendocrine Tumor, has completed, sponsored by Sue O'Dorisio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies gallium Ga 68-edotreotide positron emission tomography (PET)/computed tomography (CT) compared with indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosing patients with neuroendocrine tumors and other somatostatin receptor positive tumors. Diagnostic procedures, such as gallium Ga 68-edotreotide PET/CT, may help find and diagnose somatostatin receptor positive neuroendocrine tumors. It is not yet known whether Ga 68-edotreotide PET/CT is as effective as indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosis and staging of patients with neuroendocrine tumors.
Primary Outcome
Tumor lesions detected on 68Ga-DOTATOC PET/CT compared with tumor lesions detected on Octreoscan SPECT imaging plus high-resolution, contrast-enhanced CT.
Conditions Studied
Interventions
- PROCEDURE computed tomography
- DRUG gallium Ga 68-edotreotide
- PROCEDURE positron emission tomography/computed tomography
- RADIATION indium In 111 pentetreotide
- PROCEDURE contrast-enhanced magnetic resonance imaging
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2013-04-01 |
| Est. Completion | 2018-12-26 |
| Phase | Phase 2 |
What the finished NCT01869725 record still lists
NCT01869725 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (71% lower).
The record links to 5 conditions, with Neuroblastoma appearing as the primary indexed condition, and to 5 interventions - of which computed tomography is the first listed.
NCT01869725 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT01869725 about?
NCT01869725 is a clinical study titled "Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT". This clinical trial studies gallium Ga 68-edotreotide positron emission tomography (PET)/computed tomography (CT) compared with indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosing patients with neuroendocrine tumors and other somatostatin receptor positive tumors. Diagnostic...
What is the current status of trial NCT01869725?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2013-04-01. Estimated completion is 2018-12-26.
What conditions does trial NCT01869725 study?
This clinical trial studies the following conditions: Neuroblastoma, Neuroendocrine Tumor, Somatostatinoma, Childhood Medulloblastoma, Adult Medulloblastoma.
What interventions are being tested in trial NCT01869725?
The interventions under investigation include: computed tomography (PROCEDURE), gallium Ga 68-edotreotide (DRUG), positron emission tomography/computed tomography (PROCEDURE), indium In 111 pentetreotide (RADIATION), contrast-enhanced magnetic resonance imaging (PROCEDURE).
Who is sponsoring clinical trial NCT01869725?
This trial is sponsored by Sue O'Dorisio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01869725 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01869725's enrollment target sits among peer trials
68 42nd of 94 higher than 53 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
RECRUITING · Phase 2
-
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 2
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
RECRUITING · Phase 2
-
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
RECRUITING · Phase 2
-
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI